Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia
Information source: Heidelberg University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Pergolide (Drug)
Phase: N/A
Status: Completed
Sponsored by: Heidelberg University Official(s) and/or principal investigator(s): Daniela Roesch - Ely, MD, Principal Investigator, Affiliation: Psychiatrische Universitätsklinik Heidelberg
Summary
The objective of this study is to compare the modulation of pergolide, a D1/D2 receptor
agonist, to placebo in non-acute schizophrenic subjects under concomitant therapy with
atypical antipsychotics on specific PFC functions. Further aims are to assess the influence
of pergolide on psychopathology and extrapyramidal symptoms in comparison to placebo.
Clinical Details
Official title: Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: The D1-specific dopaminergic modulation of prefrontal functions (executive control, working memory, control of semantic association) confirmed by a complex neuropsychological battery including a non - PFC activating control task
Secondary outcome: Influence of pergolide on psychopathology symptoms and extrapyramidal symptoms in comparison to placebo measured by specific rating scales, e.g. PANSS and Calgary Depression Scale
Detailed description:
Additionally to the desired treatment of positive symptoms, the administration of typical
neuroleptics can lead to undesired side effects such as increase of negative symptomatic and
cognitive deficits. The influence of atypical neuroleptics on cognition is still not very
well studied. Furthermore there is evidence that some cognitive symptoms seen in
schizophrenia are related to a disturbance in the prefrontal cortex PFC and involve specific
subtypes of dopamine receptors, namely D1 subtypes, which predominates in this area. It is
assumed that patients with this spectrum of cognitive deficits have the worse course and
prognosis. Furthermore these deficits are more therapy resistant to the conventional current
therapy approaches. There is however some evidence pointing to a positive influence of
dopamine agonists on these deficits, but the selective effect of dopamine sub-receptors is
still not well investigated. The aim of the study is to examine whether cognitive deficits
in higher cognitive functions of the PFC such as working memory, semantic association and
executive control improves under dopamine agonistic therapy in schizophrenia and whether
this is related to selective D1 modulation.
We predict that the modulation of D1 subtype receptors improve performance in each of these
tasks. Because there is no D1 agonist available for human research we decided to use a
design comparing a dopamine agonist with mixed D1 and D2 agonistic properties (pergolide) to
placebo under a stable D2 antagonistic continuous-therapy with atypical antipsychotics. With
this design the D2-component of pergolide can be antagonized by the atypical antipsychotics
and a D1 agonistic effect can be suggested, as well as protecting patients against a
psychotic re-exacerbation. With this study we aim to bring more insight in the therapy of
PFC cognitive deficits of schizophrenia by helping to elucidate the role of selective
agonists on cognition in schizophrenic patients. I
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Non-acute in- and outpatients, with predominantly negative symptoms, and remitted
from positive symptoms like hallucinations and delusions for 1 week, with the
diagnosis of schizophrenia (ICD 10: F20) at the Psychiatry Hospital of the
Universities of Heidelberg, Hamburg-Eppendorf, Zentralinstitut für Seelische
Gesundheit Mannheim, SRH Klinikum Karlsbad - Langensteinbach (Clinical interview to
establish diagnosis with DSM-IV (M. I.N. I International Neuropsychiatric Interview _
German Version 5. 0.0)
- Verbal IQ higher than 80, as measured by the Mehrfachwahl-Wortschatz-Intelligenztest
- Visual acuity must be normal or corrected.
- Color sight intact
- Positive neuroleptics drug monitoring level
- Females must be under adequate contraception (oral hormonal contraceptive,
IntraUterineDevice)
Exclusion Criteria:
- Concomitant neurologic and internistic diseases (especially cardiovascular diseases
and others like untreated thyroid hyper-/hypofunction, liver or kidney dysfunction,
seizures or history of traumatic brain injury)
- Known allergy reaction under ergoline-therapy
- Actual history of drug abuse/addiction, concomitant other psychiatric disorder
(screened by SCID) and suicide attempt in the medical history
- Other long term pharmacological treatment which can interact with dopamine agonists
and antagonists (e. g. anticoagulants, digitoxin)
- Pregnancy and breastfeeding (anamneses and pregnancy test in urine)
- Participation in other clinical trial for the last 3 months
- History of malignant neuroleptic syndrome
Locations and Contacts
Universitätsklinikum Hamburg - Eppendorf, Hamburg 20246, Germany
SRH Klinikum Karlsbad - Langensteinbach gGmbH, Karlsbad 76307, Germany
Zentralinstitut für Seelische Gesundheit, Mannheim, 68159, Germany
Psychiatrische Universitätsklinik, Heidelberg, BW 69115, Germany
Additional Information
Starting date: October 2003
Last updated: February 9, 2010
|